Wedbush restated their buy rating on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a research note issued to investors on Monday morning, AnalystRatings.com reports. They currently have a $257.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages have also recently issued reports on ICPT. Jefferies Financial Group set a $125.00 price target on Intercept Pharmaceuticals and gave the company a buy rating in a research report on Friday, October 18th. Robert W. Baird restated a buy rating and issued a $227.00 price target on shares of Intercept Pharmaceuticals in a research report on Tuesday, December 17th. Needham & Company LLC restated a buy rating and issued a $150.00 price target on shares of Intercept Pharmaceuticals in a research report on Tuesday, December 17th. Stifel Nicolaus boosted their price target on Intercept Pharmaceuticals from $86.00 to $102.00 in a research report on Monday, November 25th. Finally, Canaccord Genuity initiated coverage on Intercept Pharmaceuticals in a research report on Monday, December 2nd. They issued a buy rating on the stock. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $141.65.

ICPT opened at $94.69 on Monday. The business’s 50-day simple moving average is $106.09 and its 200-day simple moving average is $84.93. The company has a debt-to-equity ratio of 4.02, a quick ratio of 5.49 and a current ratio of 5.49. Intercept Pharmaceuticals has a one year low of $56.76 and a one year high of $131.87. The stock has a market capitalization of $3.17 billion, a P/E ratio of -8.71 and a beta of 1.74.

In other news, insider Jason Campagna sold 732 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $113.02, for a total transaction of $82,730.64. Following the completion of the sale, the insider now directly owns 6,303 shares in the company, valued at approximately $712,365.06. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Christian Weyer sold 723 shares of the company’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $94.04, for a total value of $67,990.92. Following the sale, the executive vice president now owns 18,560 shares of the company’s stock, valued at $1,745,382.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,434 shares of company stock worth $5,599,019. 5.00% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank increased its holdings in shares of Intercept Pharmaceuticals by 7.3% during the 4th quarter. Amalgamated Bank now owns 4,701 shares of the biopharmaceutical company’s stock worth $583,000 after buying an additional 319 shares during the last quarter. CIBC World Markets Inc. acquired a new stake in shares of Intercept Pharmaceuticals during the 4th quarter worth $223,000. Amia Capital LLP acquired a new stake in shares of Intercept Pharmaceuticals during the 4th quarter worth $951,000. Financial Advocates Investment Management acquired a new stake in shares of Intercept Pharmaceuticals during the 4th quarter worth $273,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Intercept Pharmaceuticals during the 4th quarter worth $11,425,000. Institutional investors and hedge funds own 79.14% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Article: How is diluted EPS different from basic EPS?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.